中东和非洲老年性黄斑变性 (AMD) 疾病市场 – 行业趋势和 2029 年预测

市场分析和见解

中东和非洲老年性黄斑变性 (AMD) 疾病市场受到诸多因素的推动，例如老年人口增加、老年性黄斑变性 (AMD) 疾病患病率上升、产品线产品需求增加以及研发投入增加等，这些因素都推动了市场增长。目前，发达国家和新兴国家的医疗保健支出都有所增加，这有望为制造商开发新的创新产品创造竞争优势。

由于人口老龄化和预期寿命延长，发达国家老年性黄斑变性的患病率预计会增加。据估计，近 60% 的患者在出生后不久就会出现严重的视力障碍。这种疾病会导致患者眼睛中央视力模糊。发达国家对老年性黄斑变性 (AMD) 疾病治疗和诊断的需求有所增加。然而，治疗和程序的高成本以及政府对产品审批的严格规定预计将阻碍老年性黄斑变性 (AMD) 疾病市场的增长。

中东和非洲老年性黄斑变性 (AMD) 疾病市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，中东和非洲老年性黄斑变性 (AMD) 疾病市场将以 6.0% 的复合年增长率增长。

市场定义

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

• Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the Middle East and Africa incidence of early AMD. Age-related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

• Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Opportunity

•  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country Middle East and Africa. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the Middle East and Africa age-related macular degeneration (AMD) disease market.

Restraint/Challenge

• High Cost Of Aesthetic Surgical Procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the Middle East and Africa age-related macular degeneration (AMD) disease market growth.

Recent Developments

• In January 2022, Genentech, Inc announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of wet AMD and DME. This will help the company to commercialize the product in the market in the forecast period.
• In April 2022, Graybug Vision Inc. announced that the company has presented a poster presentation preclinical data at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting for GB-401 in primary open-angle glaucoma (POAG). This will increase the chances for safety and evaluation of drug in the market.

Middle East and Africa Age-Related Macular Degeneration (AMD) Disease Market Segmentation

Middle East and Africa age-related macular degeneration (AMD) disease market is categorized into is categorized into three notable segments which are based on type, end user and distribution channel. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

• Dry AMD
• Wet AMD

On the basis of type, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into dry AMD and wet AMD.

End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Home Healthcare
• Others

On the basis of end user, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare and others.

Distribution Channel

• Retail Sales
• Direct Tender

On the basis of distribution channel, the Middle East and Africa age-related macular degeneration (AMD) disease market is segmented into retail sales and direct tender.

Age-Related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights

The age-related macular degeneration (AMD) disease market is analysed and market size insights and trends are provided by type, end user and distribution channel as referenced above.

The countries covered in the age-related macular degeneration (AMD) disease report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.

South Africa is expected to dominate due to increasing technological advancement in the developing areas.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

竞争格局和老年性黄斑变性 (AMD) 疾病市场份额分析

中东和非洲老年性黄斑变性 (AMD) 疾病市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、中东和非洲业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对老年性黄斑变性 (AMD) 疾病市场的关注有关。

该市场的一些参与者包括诺华公司、拜耳公司、强生服务公司、Adverum Biotechnologies公司等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、中东和非洲与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68459